Correspondence 0001104659-24-107029 from ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V.
Date: Oct. 8, 2024 · CIK: 0001612940 · Accession: 0001104659-24-107029
AI Filing Summary & Sentiment
File numbers found in text: 333-282419
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Jessica Dickerson Acceleration Request for Registration Statement on Form F-3 File No. 333-282419
Re: ProQR Therapeutics N.V.
Dear Jessica Dickerson:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to October 10, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson, by email to AdamJohnson@goodwinlaw.com.
If you have any questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072.
Sincerely,
pROQR thERAPEUTICS
N.V.
Show Raw Text
CORRESP
1
filename1.htm
VIA EDGAR
October 8, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jessica Dickerson
Re: ProQR Therapeutics N.V.
Acceleration Request for Registration Statement on Form F-3
File No. 333-282419
Dear Jessica Dickerson:
Pursuant to Rule 461
under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”)
hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”)
be accelerated to October 10, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request,
the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement
is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Adam V. Johnson at (212) 459-7072. We
also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”)
verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Adam V. Johnson,
by email to AdamJohnson@goodwinlaw.com.
If you have any
questions regarding this request, please contact Adam V. Johnson of Goodwin Procter LLP at (212) 459-7072.
Sincerely,
pROQR thERAPEUTICS
N.V.
/s/ René
Beukema
René Beukema
Chief Corporate Development Officer and General
Counsel
cc:
Jurriaan
Dekkers, ProQR Therapeutics N.V.
Mitchell
S. Bloom, Goodwin Procter LLP
Adam
V. Johnson, Goodwin Procter LLP